LabCorp.'s proposed purchase of Dianon Systems, followed by the announcement of Welsh Carson's bid for AmeriPath, reflect different paths taken by two fierce competitors.They are also the inevitable consequence of rapid laboratory consolidation at the national level. LCA wants Dianon so that it can expand its position in cancer testing. Welsh Carson, in contrast, is a financial buyer who would have to "clean up" AmeriPath, which has run into difficulties due to its physician practice management business model.
Laboratory Corporation of America Holdings's (LCA) proposed purchase of Dianon Systems Inc. [See Deal], followed by the announcement of Welsh, Carson, Anderson & Stowe's bid for AmeriPath Inc. , reflect different paths taken by two fierce competitors. They are also the inevitable consequence of consolidation in laboratory testing at the national level.
Dianon and AmeriPath have both spent the better part of a decade striving to become national providers of anatomic pathology...